UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 27, 2023

American Oncology Network, Inc.
(Exact name of registrant as specified in its charter)

Delaware
  
001-40177
  
85-3984427
(State or other jurisdiction
of incorporation)
  
(Commission
File Number)
  
(I.R.S. Employer
Identification No.)

14543 Global Parkway, Suite 110
Fort Myers, FL
  
33913
(Address of principal executive offices)
  
(Zip Code)

(833) 886-1725
(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Class A common stock, par value $0.0001, per share
  
AONC
  
The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock
  
AONCW
  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec.240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01.
Other Events.

American Oncology Network, Inc. (the “Company”) is filing herewith as Exhibit 99.1 and 99.2, respectively, (i) its audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the three years in the period ended December 31, 2022 and (ii) its Management’s Discussion and Analysis Of Financial Condition And Results Of Operations for such periods, each of which were previously filed with the registration statement on Form S-1/A, filed with the Securities and Exchange Commission on November 20, 2023.

Item 9.01
Financial Statements and Exhibits.

Exhibit
No.
  
Description
 
Company’s audited consolidated financial statements as of December 31, 2022 and 2021 and for each of the three years in the period ended December 31, 2022
 
Company’s Management’s Discussion and Analysis Of Financial Condition And Results Of Operations
101.INS   XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH  
Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE
  Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
  
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 
AMERICAN ONCOLOGY NETWORK, INC.
     
Date: November 27, 2023
By:
/s/ David Gould
 
Name:
David Gould
 
Title:
Chief Financial Officer